The study published by Bastiaan M Privé and colleagues in The Lancet Oncology represents, to our knowledge, the first randomised phase 2 trial evaluating lutetium-177–PSMA-617 (177Lu-PSMA-617) in ...

Antibody–drug conjugates (ADCs) represent one of the most transformative advances in precision oncology over the past two decades and are increasingly positioned to replace conventional chemotherapy ...

Artificial intelligence may help doctors identify serious symptoms in childhood cancer survivors—especially when models are guided with richer prompts.

Women's HRT patches can treat prostate cancer just as effectively as standard hormone injections - but with fewer of the worst side-effects ...

As mRNA jabs move closer to clinical reality, a parallel challenge is emerging: combating the misinformation that could ...

We know this substantially reduces the overall risk of developing prostate cancer in men aged 55 and older. In conclusion, the advent of focal therapy has been a major breakthrough for prostate cancer ...

Pfizer is eyeing an earlier use of its PARP inhibitor Talzenna after a positive phase 3 trial in metastatic hormone-sensitive prostate cancer (mHSPC). The phase 3 Talapro-3 trial met its primary ...

JAMP Pharma Group is a Canadian organization headquartered in Boucherville, in the Greater Montreal area. Having experienced exceptional growth over the last 10 years, JAMP Pharma Group is active in ...

Abstract: Large multimodal models (LMM) have recently shown encouraging progress with visual instruction tuning. In this paper, we present the first systematic study to investigate the design choices ...

Merve Ceylan is a dietitian and health writer with four years of experience writing for companies in the nutrition and health industry. Some foods and drinks can worsen prostate health. Saturated fats ...

Phase II Study of BCMA Chimeric Antigen Receptor T-Cell Therapy in Patients With Newly Diagnosed Multiple Myeloma Ineligible for or Not Proceeding to Autologous Stem-Cell Transplantation (CAREMM-001) ...